| 1.49 -0.11 (-6.88%) | 10-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.14  |
1-year : | 2.4  |
| Resists | First : | 1.83 |
Second : | 2.05 |
| Pivot price | 1.66 |
|||
| Supports | First : | 1.47 |
Second : | 1.22 |
| MAs | MA(5) : | 1.58 |
MA(20) : | 1.69 |
| MA(100) : | 1.69 |
MA(250) : | 1.62 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 8.7 |
D(3) : | 9.7 |
| RSI | RSI(14): 34.8 |
|||
| 52-week | High : | 2.25 | Low : | 1.14 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ OSTX ] has closed below the lower bollinger band by 1.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ OSTX ] is to continue within current trading range. Bollinger Bands are 6.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.06 - 2.07 | 2.07 - 2.09 |
| Low: | 1.45 - 1.46 | 1.46 - 1.47 |
| Close: | 1.48 - 1.49 | 1.49 - 1.5 |
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Tue, 06 Oct 2026
OSTX Stock Holds Tight Range As Traders Probe Weak Financials - StocksToTrade
Tue, 06 Oct 2026
72.7% of treated patients survived three years, versus 45.8% in historical comparisons. - Stock Titan
Thu, 01 Oct 2026
OS Therapies has received over $3M in tax refunds and accrued over $7M in research tax credits. - Stock Titan
Wed, 16 Sep 2026
Analysts Offer Insights on NA Companies: Waystar Holding Corp. (WAY) and OS Therapies Incorporated (OSTX) - The Globe and Mail
Wed, 09 Sep 2026
Analysts Offer Insights on NA Companies: OS Therapies Incorporated (OSTX) and Concentra Group Holdings Parent, Inc. (CON) - The Globe and Mail
Tue, 08 Sep 2026
An interim cancer-trial analysis found 71.2% three-year survival versus 45.8% in a historical group. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|